● Recruiting

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

Condition: Lymphoma · Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

PhasePhase 2

Planned participants65

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).

This description comes directly from the study's public registry record.

Talk to the study team

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com

First line of the email MUST contain NCT # and Site #.

Always discuss trial participation with your own doctor first.

Locations (40)

University Of Colorado	Aurora, Colorado, United States	Recruiting
Moffitt Cancer Center	Tampa, Florida, United States	Recruiting
Robert H. Lurie Comprehensive Cancer Center of Northwestern University	Chicago, Illinois, United States	Recruiting
Dana-Farber Cancer Institute	Boston, Massachusetts, United States	Recruiting
Washington University School of Medicine in St. Louis	St Louis, Missouri, United States	Recruiting
Rutgers Cancer Institute of New Jersey	New Brunswick, New Jersey, United States	Recruiting
Roswell Park Comprehensive Cancer Center	Buffalo, New York, United States	Recruiting
Memorial Sloan Kettering Cancer Center	New York, New York, United States	Recruiting
Cleveland Clinic	Cleveland, Ohio, United States	Recruiting
The Ohio State University Comprehensive Cancer Center	Columbus, Ohio, United States	Recruiting
University of Pennsylvania	Philadelphia, Pennsylvania, United States	Recruiting
Sarah Cannon Research Institute Oncology Partners	Nashville, Tennessee, United States	Recruiting

+ 28 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07015242